Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (686)	10/18/2004 3:26:06 AM
From: Icebrg	Respond to of 1022

Peregrine Pharmaceuticals Announces Successful Completion of its Antibody Humanization Project with AERES Biomedical Monday October 18, 3:00 am ET [Posted mainly because the information provided on AERES. I didn't even know they existed]. TUSTIN, Calif., October 18 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM - News) announced today that AERES Biomedical Ltd. (London, UK) had successfully completed the humanization of its 3G4 antibody that recognizes the phospholipid, phosphatidylserine. The 3G4 antibody is part of Peregrine's Anti-Phospholipid Therapy(APT) platform technology. Human or humanized monoclonal antibodies are ideal components of drugs that may be administered multiple times to individual patients because they are expected to not be recognized as foreign by the patient's immune system. "The humanized version of the 3G4 antibody is an important addition to Peregrine's VTA and APT platform technologies," said Steve King, Peregrine's president and chief executive officer. "We will begin preparing the humanized 3G4 antibody for cGMP manufacturing and evaluate the antibody for the treatment of cancer and viral diseases. The humanized antibody will also be evaluated as a carrier for therapeutic agents for vascular targeting applications." Dr. Tarran Jones, chief executive officer of AERES, said, "We are delighted to have been able to provide Peregrine with a humanized version of its 3G4 antibody. The project was completed on schedule and the resulting antibody retained all desired binding characteristics. This collaborative project marks the 25th monoclonal antibody that we have successfully humanized using our proprietary humanization technology." About AERES Biomedical, Ltd. AERES Biomedical Ltd. is a privately owned drug development company which has been active in the development and exploitation of antibody humanization since 1988. AERES is now applying its expertise to the development of humanized therapeutic antibodies, both in-house and with its collaborative partners. Over the past 16 years, AERES scientists have radically improved this technology and developed a portfolio of related antibody engineering skills. With nearly 30 successful collaborative R&D programs with the biopharmaceutical industry, which has enabled at least 7 humanized antibodies to enter clinical trials, AERES has established a world-wide reputation for its expertise in antibody humanization. In addition, AERES has a significant track record of success in maximizing the expression of antibody genes in mammalian cells. As a consequence, AERES is able to provide its commercial collaborators with drug candidates that move rapidly through clinical development with an increased probability of reaching the market.